Candace Mainor
Georgetown University · MedStar Georgetown University Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Candace Mainor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:35 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05256745 · RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast CancerGeorgetown University · recruiting · Cancer Related Cognitive Decline, Non-metastatic Breast Cancer · principal investigator
- Ph2NCT03535506 · Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for SurgeryGeorgetown University · terminated · DCIS · principal investigator
- Ph2NCT03487666 · OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual DiseaseGeorgetown University · completed · Triple Negative Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:35 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Nat Commun · 202434 citationsRCR 4.0
- HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.Breast Cancer Res Treat · 20227 citationsRCR 0.7
- Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.J Am Med Inform Assoc · 20251 citationsRCR 0.3